Bronchiectasis - Pipeline Review, Q1 2011 by GlobalMarketsDirect

VIEWS: 1 PAGES: 36

Bronchiectasis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Bronchiectasis - Pipeline Review, Q1 2011', provides an overview of the Bronchiectasis therapeutic pipeline. This report provides information on the therapeutic development for Bronchiectasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiectasis. 'Bronchiectasis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchiectasis.
- A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchiectasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-s

More Info
									Bronchiectasis – Pipeline Review, Q1 2011




                   Bronchiectasis - Pipeline Review, Q1 2011
                                                                                     Reference Code: GMDHC202IDB

                                                                                     Publication Date: March 2011




Bronchiectasis – Pipeline Review, Q1 2011                                                                      GMDHC202IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                    Page(1)
Bronchiectasis – Pipeline Review, Q1 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                                2
List of Tables                                                                                                                   3
List of Figures                                                                                                                  4
Introduction                                                                                                                     5
    Global Markets Direct Report Coverage                                                                                        5
Bronchiectasis Overview                                                                                                          6
Therapeutics Development                                                                                                         7
    An Overview of Pipeline Products for Bronchiectasis                                                                          7
Bronchiectasis Therapeutics under Development by Companies                                                                       9
Bronchiectasis Therapeutics under Investigation by Universities/Institutes                                                      11
Late Stage Products                                                                                                             12
    Comparative Analysis                                                                                                        12
Mid Clinical Stage Products                                                                                                     13
    Comparative Analysis                                                                                                        13
Early Clinical Stage Products                                                                                                   14
    Comparative Analysis                                                                                                        14
Pre-Clinical Stage Products                                                                                                     15
    Comparative Analysis                                                                                                        15
Bronchiectasis Therapeutics - Products under Development by Companies                                                           16
Bronchiectasis Therapeutics - Products under Investigation by Universities/Institutes                                           17
Companies Involved in Bronchiectasis Therapeutics Development                                                                   18
    Aradigm Corporation                                                                                                         18
    Gilead Sciences, Inc.                                                                                                       18
    Discovery Laboratories, Inc.                                                                                                19
    Bayer AG                                                                                                                    19
    Pharmaxis Ltd.                                                                                                              20
    RegeneRx Biopharmaceuticals, Inc.                                                                                           20
    Aridis Pharmaceuticals LLC                                                                                                  21
    NexBio, Inc.                                                                                                                21
Bronchiectasis - Therapeutics Assessment                                                                                        22
    Assessment by Monotherapy Products                                                                                          22
    Assessment by Combination Products                                                                                          23
    Assessment by Route of Administration                                                                                       24
    Assessment by Molecule Type                                                                                                 26
Late Stage Drug Profiles – Companies                                                                                            28
    Bronchitol - Drug Profile                                                                                                   28
         Product Description                                                                                                    28
         Mechanism of Action                                                                                                    28
         R&D Progress                                                                                                           28
Late Stage Drug Profiles – Universities/Institutes                                                                              29
    Azithromycin - Drug Profile                                                                                                 29
         Product Description                                                                                                    29
         Mechanism of Action                                                                                                    29
         R&D Progress                                                                                                           29
    Bronchiectasis - Featured News                                                                                              31
         Oct 20, 2010: Aradigm Reports Successful Phase IIb Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin           31




Bronchiectasis – Pipeline Review, Q1 2011                                                                 GMDHC202IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                         Page(2)
Bronchiectasis – Pipeline Review, Q1 2011


         Sep 17, 2010: Aradigm Presents Results Of ARD-3100 For Treatment Of Bronchiectasis At 2010 European Respiratory Society Annual
         Congress                                                                                                                       32
         Sep 17, 2010: Aradigm Presents Results Of ARD-3150 For Treatment Of Bronchiectasis At 2010 European Respiratory Society Annual
         Congress                                                                                                                       32
         Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis                 33
         Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT                               33
         Jan 16, 2007: Aradigm Receives FDA Orphan Drug Designation For Liposomal Ciprofloxacin For Bronchiectasis                     34
Appendix                                                                                                                               35
    Methodology                                                                                                                        35
         Coverage                                                                                                                      35
         Secondary Research                                                                                                            35
         Primary Research                                                                                                              35
         Expert Panel Validation                                                                                                       36
    Contact Us                                                                                                                         36
    Disclaimer                                                                                                                         36




Lis t o f Ta b le s
Number of Products Under Development for Bronchiectasis, Q1 2011                                                                        7

Products under Development for Bronchiectasis – Comparative Analysis, Q1 2011                                                           8

Comparative Analysis by Late Stage Development, Q1 2011                                                                                12

Comparative Analysis by Mid Clini
								
To top